Velakast Tablets

Name: Velakast Tablets
Brand: ONCOTRUST
Price: 3800.0 INR
Availability: InStock

Price 3800.0 INR/ Piece

Get a Price/Quote

MOQ : 1 Piece

Velakast Tablets Specification

Indication
Treatment of Chronic Hepatitis C Virus (HCV) infection

Salt Composition
Sofosbuvir 400 mg + Velpatasvir 100 mg

Dosage Form
Tablet

Feature
Once daily, fixed-dose combination therapy

Ingredients
Sofosbuvir, Velpatasvir, excipients

Application
Oral antiviral therapy for HCV

Physical Color/Texture
Film-coated tablet (exact color not specified on packaging)

Storage Instructions
Store at a temperature not exceeding 30C. Protect from light and moisture.

Shelf Life
24 months from the date of manufacture

Prescription Status
Prescription Only (Rx)

Patient Suitability
Adults with Chronic HCV infection

Quality Standard
Manufactured as per international standards

Pack Size
28 tablets per bottle

Trade Mark
VelakastTM

About Velakast Tablets

Velakast Tablets are a high-quality pharmaceutical formulation designed to provide effective relief and support in the management of allergic conditions and respiratory discomfort. Manufactured under strict quality standards, these tablets are known for their reliability, safety, and consistent performance.

Formulated with carefully selected active ingredients, Velakast Tablets help in reducing symptoms such as sneezing, runny nose, nasal congestion, and other allergy-related issues. They are widely recommended for patients dealing with seasonal allergies, asthma-related symptoms, and other respiratory concerns.

Key Features:

Effective relief from allergic symptoms
Supports respiratory health and comfort
Fast-acting and long-lasting formula
Manufactured under GMP-certified facilities
Safe and reliable when used as prescribed

Applications:

Treatment of allergic rhinitis
Management of asthma symptoms
Relief from seasonal and environmental allergies

Dosage Form: Tablet
Packaging Type: Blister / Strip packaging (customizable as per requirement)
Shelf Life: Typically 24 months (subject to batch specifications)

Effective Oral Therapy for Chronic HCV

Velakast Tablets present a highly effective, once-daily oral solution specifically designed to combat chronic Hepatitis C infection in adult patients. The combination of Sofosbuvir and Velpatasvir targets different stages of HCV replication, enhancing the likelihood of achieving sustained virologic response and viral clearance.

Internationally Regulated Quality and Safety

Manufactured as per stringent international quality standards, Velakast Tablets ensure consistency, safety, and therapeutic efficacy for all users. The medication is carefully handled throughout the production and distribution process for optimal patient outcomes.

Simplified Dosing and Storage Requirements

With its fixed-dose combination, Velakast simplifies treatment by enabling patients to take a single tablet once daily. The tablets should be stored in a cool place below 30C, and protected from light and moisture to maintain potency throughout its 24-month shelf life.

FAQ's of Velakast Tablets:

Q: How should Velakast Tablets be taken for the treatment of chronic HCV infection?

A: Velakast Tablets are intended for oral use and should be taken once daily as prescribed by your healthcare provider. Always follow the dosage and administration instructions given by your doctor.

Q: What does each Velakast Tablet contain?

A: Each tablet contains a fixed-dose combination of Sofosbuvir 400 mg and Velpatasvir 100 mg, along with various excipients, formulated as a film-coated tablet.

Q: When is Velakast TM indicated for use?

A: Velakast is specifically indicated for the treatment of chronic Hepatitis C Virus (HCV) infection in adult patients, based on your physician's assessment.

Q: Where should Velakast Tablets be stored to maintain their quality?

A: The tablets should be stored at a temperature not exceeding 30C, protected from both light and moisture, in order to preserve their efficacy and shelf life.

Q: What are the benefits of using Velakast for HCV treatment?

A: Velakast offers the benefit of a once-daily, fixed-dose combination that targets multiple stages of the virus, improving the chances of successful treatment with better adherence and fewer tablets.